CEP55

Across TCGA pan-cancer cohorts, CEP55 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CEP55 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CEP55 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CEP55 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BLCA, LIHC, and UCEC are the cancer types where CEP55 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.881	0.262	.007	29	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CEP55–BLCA (DFS)

Open the BLCA breakdown →